CNS-targeted obesity (non-incretin) : Tradipitant (NK1R antagonist, Vanda, approved Dec 2025) and CNS delivery platform deals (Ophidion/Neuronasal, Dec 2025) point to a sparse but emerging non-incretin route
They stimulate the central nervous system (CNS) and are FDA-approved to treat attention-deficit hyperactivity disorder (ADHD), a neurodevelopmental disorder associated with hyperactivity, inattention, and impulsivity
One study compared them directly and found that gastric emptying half-time was delayed by 52 minutes with lixisenatide (short-acting) but only 25 minutes with liraglutide (long-acting) [2]
Semaglutide just makes this process easier to maintain
Oxidative stress and immune system dysfunction in autism spectrum disorders
Oral Solution: For those who have difficulty swallowing tablets, sertraline is also available as an oral solution